IBO vs PATH
Impact BioMedical, Inc. (IBO) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Impact BioMedical, Inc. (IBO) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IBO revenue for 2025-09-30 was $18.0K. Net income was -$1.5M. IBO currently screens at market cap $7.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IBO currently screens at market cap $7.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IBO and PATH stock pages for the full models.
Not investment advice.